English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Know the tumor stage of breast cancer and identify the immunohistochemical markers are important in the evaluation of predictive and prognostic factors, in the differential diagnosis of breast lesions and in the determination of the possible origin of metastatic neoplasms, besides helping to define the type of treatment. Methodology: Cross-sectional and quantitative study of patients diagnosed with breast cancer, submitted to treatment at the Ceara Cancer Institute (ICC) mastology service from 2008 to 2012. Describe the main clinical and epidemiological characteristics of breast cancer treated at Haroldo Juacaba Hospital Ceara Cancer Institute (ICC): Identify types of breast cancer; to evaluate the initial staging, correlating axillary status, local and systemic treatment; to analyze the immunohistochemical profile through receptors standardized by the pathology department of the Hospital, correlating them with the current molecular classification of breast cancer. Results: A total of 453 medical records were included. 41.5% of the patients had tumor in the T2 stage, 15.9% in the T1 stage, 12.6% in the T4 stage, 11.9% and in the T3 stage, 11.3% had tumor in situ. As for lymph nodes, 61.6% of them were in N0, 24.5% in N1, 13.0% in N2 and 0.9% in N3. 57% of the patients were sentinel node biopsy, 31% of the positive frozen. No significant amount of distant metastasis was identified. Regarding tumor type, 89.38% are ductal, 5.09% are lobular, 0.88% are tubular, 0.66% are mucinous and 7.30% are other types or mixed. With hormone receptor analysis, we obtained 38.3% of luminal type A tumors, 32.8% luminal type B, 21.8% Triple Negative type and 7.2% CERB B2 type. Conclusion: Patients were predominantly classified at the IIA clinical stage. The invasive ductal carcinoma subtype is the most prevalent and there is predominance of the luminal molecular pattern, with discrete superiority of luminal pattern A over luminal B.

Prognostic Factors in Breast Cancer: From Staging to the Immunohistochemical Profile of Patients with Breast Cancer in a Reference Hospital of Ceara - Brazil